Partnership opportunities

Your partner in success

A number of factors make Celsion an extremely attractive commercialization partner and investment opportunity.

Clinical focus on novel treatments for patients with minimal options.
Agreed pivotal trial programs with the FDA for two indications under study.
Unique heat activated liposome technology platform can be used to encapsulate and deliver many therapeutic agents for the treatment of a wide variety of indications.
Encapsulations of approved therapeutic agents in a novel format for treatment of established indications reduces the complexity of clinical programs and increases the speed of approval thereby decreasing the time to market.
Financial resources available to enable completion of Phase III HCC indication sufficient to support an NDA filing.
Executive team with extensive pharmaceutical development and commercialization experience.

Celsion is poised to build on its past successes and, with the right partners and investors on board, advance the efficacy and the tolerability of chemotherapeutics, helping to ensure better patient outcomes and improved quality of life.

For more partnering information please contact

Raj Prabhakar
Executive Director, Strategic Planning & Business Development
997 Lenox Drive, Suite 100
Lawrenceville, NJ 08648, USA
T 609.896.9100
F 609.896.2200
celsion@celsion.com
www.celsion.com